Expertise in
4
conditions

Irwindeep Sandhu

Edmonton, AB, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
4
conditions
Edmonton, AB, CA 

Overview

Irwindeep Sandhu practices practicing medicine in Edmonton, Canada.

Sandhu is highly rated in 4 conditions, according to our data. Their clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Febrile Neutropenia, and Acute Myeloid Leukemia (AML).

They are actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 8 clinical trials.

Locations

Edmonton, AB T6G1Z2, Canada
Other Locations
AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study
D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study
Enrollment Status: Completed
Publish Date: September 28, 2021
Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study
Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)
A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)
Enrollment Status: Withdrawn
Publish Date: April 05, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

45 Total Publications

FOXM1 and NFκB Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma.
FOXM1 and NFκB Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma.
Journal: Cells
Published: March 21, 2026

Frequently Asked Questions about Irwindeep Sandhu

Is Irwindeep Sandhu a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Irwindeep Sandhu is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Irwindeep Sandhu participate in research or clinical trials?

Yes. Irwindeep Sandhu has published 45 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Irwindeep Sandhu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sandhu's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile